An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis.

@article{Seidman2005AnEO,
  title={An evaluation of butoconazole nitrate 2\% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis.},
  author={Larry S. Seidman and Campbell K Skokos},
  journal={Infectious diseases in obstetrics and gynecology},
  year={2005},
  volume={13 4},
  pages={
          197-206
        }
}
BACKGROUND It is estimated that as many as 13 million cases of vulvovaginal infection occur in the United States annually, the majority of which are the result of Candida albicans infection. The symptoms of vulvovaginal infections are often painful and distressing to the patient. The objective of this study was to compare the time to symptomatic relief of vulvovaginal candidiasis (VVC) with butoconazole nitrate 2% Site Release vaginal cream (Gynazole-1) and oral fluconazole 150 mg tablets… Expand
Safety and efficacy of a new imidazole fungicide, Sertaconazole, in the treatment of fungal vulvo-vaginitis: a comparative study using Fluconazole and Clotrimazole
TLDR
Sertaconazole appeared to work well with lowest recurrence in fungal vulvo-vaginitis and had similar effectiveness and less side-effect as compared with Fluconazole and Clotrimazole. Expand
Efficacy of a vaginal tablet as a Persian medicine product on vulvovaginal candidiasis: a double-blind, randomised, placebo-controlled trial
TLDR
The findings suggest the ‘ward’ vaginal tablet could ameliorate vulvovaginal candidiasis and future larger studies are recommended due to compare the therapeutic effect of the 'ward' vaginal tablet with common treatments. Expand
For vaginal candidiasis, does topical treatment provide quicker and more effective symptom relief than oral treatment?
TLDR
The weight of evidence points to no difference in clinical cure rates for oral therapy compared with topical therapy, although fewer patients receiving oral therapy have recurrence of symptoms at one month (SOR: B, RCT). Expand
Treatment of recurrent vulvo-vaginal candidiasis with sustained-released butoconazole pessary.
TLDR
A sustained-release (SR) bioadhesive vaginal cream (2% butoconazole nitrate) has incorporated VagiSite technology, a topical drug delivery system that allows SR of the drug to be incorporated in the treatment of two cases of RVVC. Expand
Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis
TLDR
Fluconazole appeared to be the best drug for the treatment of VVC according to the analysis, and the quality of included studies provided an evidence-based reference for clinical use. Expand
Activities of fluconazole in combination with terbinafine against non-albicans Candida species isolated from the patients with recurrent vulvovaginal candidiasis in comparison with ciclopirox olamine
TLDR
Most of isolates were resistant against fluconazole and terbinafine, and combination of these drugs did not affect clinical isolates, but cyclopirox olamine with the lowest mean of MICs and MFCs showed the highest activity in non-albicans isolates. Expand
Patient preferences and treatment safety for uncomplicated vulvovaginal candidiasis in primary health care
TLDR
This work describes a protocol of a multicentric prospective observational study with one year follow up, to describe the women's reasons and preferences to choose the way of administration (oral vs topical) in the treatment of not complicated candidal vaginitis. Expand
Evidence-Based Management of Recurrent Vulvovaginal Candidiasis
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5-8% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no gold standardExpand
Recent advances on topical antimicrobials for skin and soft tissue infections and their safety concerns
TLDR
Topical antimicrobials retain the following features: they are able to escape the enzymatic degradation and rapid clearance in the gastrointestinal tract or the first-pass metabolism during oral administration, resulting in a reduction of microbial proliferation at infected skin sites. Expand
Spectrophotometric Determination of Fluconazole, Voriconazole and Butoconazole nitrate by Ion-Pair Formation with Rose Bengal Reagent.
ABSTRACT The reactions of Rose bengal reagent (Rbeng) with three antifungal drugs Fluconazole (FLZ), Voriconazole (VRZ) and Butoconazole nitrate (BTZ) had been studied for the development of simple,Expand
...
1
2
...

References

SHOWING 1-10 OF 24 REFERENCES
Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group.
TLDR
This clinical trial demonstrated that butoconazole 1-BSR is an effective and safe alternative to longer-term therapy with miconazole nitrate (seven days) for vulvovaginal candidiasis. Expand
Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study.
TLDR
A randomized, double-blind placebo trial compared the efficacy of a single oral 200 mg dose of fluconazole with the application of terconazoles 80 mg vaginal suppository daily for 3 days to treatCandida vaginitis in women in their childbearing years. Expand
Three-Day Treatment With Butoconazole Nitrate for Vulvovaginal Candidiasis
A multicenter clinical trial of 274 patients compared the efficacy and safety of a new vaginal antifungal compound, butoconazole nitrate cream 2% (butoconazole), to clotrimazole vaginal tablets 200Expand
Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study.
TLDR
Fluconazole in single dose warrants optimal compliance in patients who frequently experience more than one episode of VVC with a dramatic decrease of signs and symptoms 7 days after treatment initiation. Expand
Comparative Study of Fluconazole and Clotrimazole for the Treatment of Vulvovaginal Candidiasis
TLDR
It is recommended that a single oral dose of 150 mg of fluconazole be given as an alternative method of treating vulvovaginal candidiasis, but the cost is higher than for clotrimazole. Expand
Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group.
TLDR
Fluconazole administered as a single 150 mg oral dose proved to be as safe and effective as 7 days of intravaginal clotrimazole therapy for Candida vaginitis. Expand
A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial.
TLDR
This double-blind multicentre study showed that a single oral 150 mg dose of fluconazole was as effective as 5 days of oral ketoconazole medication in the treatment of vaginal candidiasis. Expand
Vaginal retention of 2% butoconazole nitrate cream: comparison of a standard and a sustained-release preparation.
The purpose of this study was to establish the length of time that butoconazole nitrate 2% standard cream and sustained-release cream could be detected in the vagina after a single administration ofExpand
Treatment of candidal vaginitis: A prospective randomized investigator‐blind multicenter study comparing topically applied econazole with oral fluconazole
TLDR
No significant differences were observed at the 7‐10 and the 80‐100‐day follow‐up visits, although fluconazole tended to be more efficacious, and three women out of 4 preferred oral to local therapy of candidal vaginitis. Expand
Treatment of vaginal candidosis with fluconazole.
TLDR
There was a higher mycological cure rate in the rectum of fluconazole patients which enables the elimination of rectal fungal infection as a source of homologous reinfection. Expand
...
1
2
3
...